📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Biomea Fusion

1.1 - Company Overview

Biomea Fusion Logo

Biomea Fusion

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.

Products and services

  • FUSION™ System: A proprietary platform that architects and develops novel covalent small-molecule therapies targeting high-value genetic drivers in cancer and metabolic diseases
  • BMF-219: An oral covalent menin inhibitor that targets genetically defined cancers—AML, ALL, DLBCL, MM, CLL—and type 2 diabetes by enabling beta-cell proliferation and function
  • BMF-500: An orally bioavailable covalent small-molecule FLT3 inhibitor engineered for treating AML and potentially in combination with other therapies, offering high potency and selectivity

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Biomea Fusion

Indaptus Therapeutics Logo

Indaptus Therapeutics

HQ: United States Website
  • Description: Provider of an immunotherapy platform leveraging attenuated and killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune pathways for anti-tumor and anti-viral activity. Offers Decoy20, a Phase 1 therapeutic candidate using engineered bacteria to stimulate anti-tumor defenses, and an intravenous pipeline targeting cancers and infectious diseases with high unmet needs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Indaptus Therapeutics company profile →
Medite Cancer Diagnostics Logo

Medite Cancer Diagnostics

HQ: United States Website
  • Description: Provider of development, manufacture, and distribution as a mid-sized industrial corporation.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Medite Cancer Diagnostics company profile →
Five Prime Therapeutics Logo

Five Prime Therapeutics

HQ: United States Website
  • Description: Provider of cancer treatment biotechnology, discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant human proteins to find the best for each clinical indication, enabled by its ProScreen Engine for rapid production and screening.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Five Prime Therapeutics company profile →
AroCell Logo

AroCell

HQ: Sweden Website
  • Description: Provider of biomarker-based diagnostic tests for cancer prognosis, monitoring, and follow-up, including the TK 210 ELISA measuring TK1 as a marker of increased cell turnover. Offers Oncology Diagnostics tools to capture critical clinical data for cancer patient management, and TUBEX TF, a rapid, sensitive in vitro test for detecting acute typhoid fever caused by Salmonella enterica.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full AroCell company profile →
Northern Biologics Logo

Northern Biologics

HQ: Canada Website
  • Description: Provider of state-of-the-art antibody discovery targeting novel and challenging oncology and fibrosis targets, developing therapeutic antibody candidates derived from a phage display platform developed and refined by world-leading researchers at the University of Toronto.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Northern Biologics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Biomea Fusion

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Biomea Fusion

2.2 - Growth funds investing in similar companies to Biomea Fusion

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Biomea Fusion

4.2 - Public trading comparable groups for Biomea Fusion

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Biomea Fusion

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Biomea Fusion

What does Biomea Fusion do?

Biomea Fusion is a provider of precision oncology and metabolic disease therapeutics based on novel covalent small molecules, including BMF-219, an oral investigational menin inhibitor for genetically defined cancers (AML, ALL, DLBCL, MM, CLL) and type 2 diabetes by enabling beta-cell proliferation and function; BMF-500, an investigational oral FLT3 inhibitor for AML; and the FUSION System, a platform for designing covalent small molecule therapies.

Who are Biomea Fusion's competitors?

Biomea Fusion's competitors and similar companies include Indaptus Therapeutics, Medite Cancer Diagnostics, Five Prime Therapeutics, AroCell, and Northern Biologics.

Where is Biomea Fusion headquartered?

Biomea Fusion is headquartered in United States.

How many employees does Biomea Fusion have?

Biomea Fusion has 1,000 employees 🔒.

When was Biomea Fusion founded?

Biomea Fusion was founded in 2010 🔒.

What sector and industry vertical is Biomea Fusion in?

Biomea Fusion is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Biomea Fusion

Who are the top strategic acquirers in Biomea Fusion's sector and industry

Top strategic M&A buyers and acquirers in Biomea Fusion's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Biomea Fusion?

Top strategic M&A buyers groups and sectors for Biomea Fusion include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Biomea Fusion's sector and industry vertical

Which are the top PE firms investing in Biomea Fusion's sector and industry vertical?

Top PE firms investing in Biomea Fusion's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Biomea Fusion's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Biomea Fusion's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Biomea Fusion's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Biomea Fusion include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Biomea Fusion's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Biomea Fusion?

The key public trading comparables and valuation benchmarks for Biomea Fusion include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Biomea Fusion for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Biomea Fusion with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Biomea Fusion's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Biomea Fusion with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Biomea Fusion's' sector and industry vertical?

Access recent funding rounds and capital raises in Biomea Fusion's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Biomea Fusion

Launch login modal Launch register modal